AbbVie Q1 revenue $12.2B down 9.7%; GAAP EPS $0.13, adj. EPS $2.46; raises FY guidance

AbbVie Inc.

2023-Q1 EPS reported $0.13 revenue$12,225,000,000

Q1 net revenues $12.225B, down 9.7% reported / 8.3% operational; GAAP diluted EPS $0.13 (down 94.8%), adj. diluted EPS $2.46 (down 22.2%).
Immunology portfolio $5.587B (-9%); Humira $3.541B (-25.2%), Skyrizi $1.360B (+44.7%), Rinvoq $686M (+47.5%).
Hematologic oncology $1.416B (-14%); Imbruvica $878M (-25.2%), Venclexta $538M (+13.7%).
Raises FY 2023 adj. diluted EPS guidance from $10.62-$11.02 to $10.72-$11.12.
Neuroscience $1.695B (+13.9%); aesthetics $1.300B (-5.4%).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AbbVie Inc. reported the first quarter ended March 31, 2023 results: revenue $12.225 Billion, EPS $0.13. Guidance raised.

Period: the first quarter ended March 31, 2023
Revenue: $12.225 Billion
EPS: $0.13
Guidance: raised
Result: reported results

Exact text from the filing

AbbVie Reports First-Quarter 2023 Financial Results • Reports First-Quarter Diluted EPS of $0.13 on a GAAP Basis, a Decrease of 94.8 Percent; Adjusted Diluted EPS of $2.46, a Decrease of 22.2 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share related to Acquired IPR&D and Milestones Expense • Delivers First-Quarter Net Revenues of $12.225 Billion, a Decrease of 9.7 Percent on a Reported Basis and 8.3 Percent on an Operational Basis

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

AbbVie Inc. filing history →

Source: SEC EDGAR

accession 0001551152-23-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.